Faculty Collaboration Database

Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol 2006 Nov;60(2):99-111

Date

10/10/2006

Pubmed ID

17027279

DOI

10.1016/j.critrevonc.2006.04.005

Scopus ID

2-s2.0-33750339323 (requires institutional sign-in at Scopus site)   31 Citations

Abstract

Malignant gliomas are devastating tumors associated with poor prognosis. Standard treatment has been surgery followed by radiotherapy while the role of chemotherapy has remained controversial. Concomitant and adjuvant treatment with temozolomide has recently been shown to improve survival in patients with glioblastoma. While it seems intuitive to apply this regimen to patients with anaplastic gliomas which have traditionally been considered more chemosensitive, chemotherapy has not been shown to prolong life in patients with anaplastic gliomas. Despite promising preclinical and early clinical results, there is currently not enough level 1 evidence to justify concomitant and adjuvant temozolomide as standard therapy for patients with newly diagnosed anaplastic gliomas. Further investigation is needed to better define the role of chemotherapy in patients with anaplastic gliomas. Trials evaluating chemoradiotherapy as well as targeted therapeutic agents are the subject of further research.

Author List

Siker ML, Chakravarti A, Mehta MP

Author

Malika L. Siker MD Associate Dean, Associate Professor in the Radiation Oncology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antineoplastic Agents, Alkylating
Astrocytoma
Brain Neoplasms
Carcinoma
Chemotherapy, Adjuvant
Clinical Trials as Topic
Combined Modality Therapy
DNA Modification Methylases
DNA Repair Enzymes
Dacarbazine
Humans
Oligodendroglioma
Salvage Therapy
Tumor Suppressor Protein p14ARF
Tumor Suppressor Proteins